title: [Experiences with adjuvant prostaglandin therapy in vascular surgery interventions].
abstract: Two prospective randomized trials were referred. In the first study 50 patients with femorotibial greater saphenous vein in situ bypasses were treated intraarterially with 0.2 ng PGE 1/kg body weight/min and 15,000 i.U. of heparine continuously. The control group of 50 patients also got 15,000 i.U. of heparine and 3 x 0.5 g of Aspirin. We observed 2 (4%) immediate occlusions in the PGE 1 group and 7 (14%) immediate occlusions in the control group. This difference proved to be statistically significant. In the second study 83 patients with three level occlusions (ilio-femoro-tibial) in stage III and IV were treated with a profundaplasty. 42 patients received 60 micrograms PGE 1 in 250 ml saline twice daily. The control group of 41 patients only got twice 250 ml saline over a period of three weeks. In the PGE 1 group 26 patients (61%) showed disappearance of rest pain and healing of necrotic lesions, whereas in the control group this could only be achieved in 15 patients (35%). The difference proved to be statistically significant.
authors.affiliation: Kurhessisches Diakonissenhaus, Gefässchirurgische Abteilung, Kassel.
authors.forename: J D
authors.initials: JD
authors.lastname: Gruss
authors.forename: W
authors.initials: W
authors.lastname: Hiemer
authors.forename: A
authors.initials: A
authors.lastname: Kroiss
authors.forename: C
authors.initials: C
authors.lastname: Geissler
mesh_terms: D000527:Alprostadil / Q000008:administration & dosage*; D001166:Arteriovenous Shunt, Surgical; D001241:Aspirin / Q000008:administration & dosage; D006083:Graft Occlusion, Vascular / Q000188:drug therapy*; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007511:Ischemia / Q000601:surgery*; D007866:Leg / Q000098:blood supply*; D011183:Postoperative Complications / Q000188:drug therapy*; D011446:Prospective Studies
chemical_list: D006493:Heparin; D000527:Alprostadil; D001241:Aspirin
vernacular_title: Erfahrungen mit der adjuvanten Prostaglandin-Therapie bei gefässchirurgischen Eingriffen.